DIAGNOS inc. ADK

BROSSARD, Quebec, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a Section 513(g) Request for Information to the U.S. Food and Drug Administration (“FDA”) regarding the classification and applicable regulatory requirements for its CARA System. The submission f

MIAMI, Sept. 22, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 96th Emerging Growth Conference on September 23 & 24, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting c

BROSSARD, Quebec, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health pathologies using Artificial Intelligence (AI) techniques, announces that the 2026 annual general meeting of shareholders (the “Meeting”) will be held on September 30, 2026, at 10:00 a.m., in person, at Alt Quartier DIX30 Hotel, 6500 de Rome Blvd, 2nd floor, Brossard, QC, J4Y 0B6, for the f

BROSSARD, Quebec, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that today, August 13, 2026, it has received Medical Device Marketing Authorization for the CARA System (CARA) from the Saudi Food and Drug Authority (SFDA).The version of CARA licensed in Saudi Arabia includes detecti

BROSSARD, Quebec, July 27, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that, on July 23, 2026, it has received a Health Canada Medical Device Licence authorizing the commercialization of its CARA System in Canada. CARA System technology integrates AI-powered analysis modules within a sing

BROSSARD, Quebec, July 07, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of critical health issues using advanced Artificial Intelligence (AI) techniques, announces that it intends to amend the expiry date of 6,715,369 stock warrants (each a “Warrant”) from August 5, 2026 to June 5, 2027 (the “Amendment”). The Warrants were issued as part of a non-brokered private placement of units i

BROSSARD, Quebec, June 18, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces its intention to settle two (2) arm’s-length demand loans in the aggregate amount of C$125,000 by the issuance of an aggregate number of 625,000 common shares of the Corporation (each a “Share”) at an issue price of C$0,20 per Shar

BROSSARD, Quebec, June 16, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that it has submitted a modified and updated application for a Class II medical device licence for its proprietary CARA System platform to Health Canada. Following detailed guidance from Health Canada in the fall of 2025,

BROSSARD, Quebec, June 12, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, announces a grant of an aggregate number of 1,500,000 stock options to directors and officers of the Corporation. The date of the grant is June 11, 2026. The expiry date to which the stock options can be exercised is June 11, 2031. Stock opt

MIAMI, June 10, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compani

MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 93rd Emerging Growth Conference on June 10 & 11, 2026. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the Conference here. Submit Questions for any of the presenting compani

DIAGNOS invites individual and institutional investors, as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. BROSSARD, Quebec, June 03, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a Corporation dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that Mr. André Larente, CEO of DIAGNOS, has

BROSSARD, Quebec, April 08, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to provide an update to the press release dated January 13, 2026 on the regulatory pathway for the future version of its flagship product CARA, which incorporates eye-related disease detection algorithms, and April 1, 2026 announceme

BROSSARD, Quebec, April 01, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a company dedicated to the early detection of eye-related health using Artificial Intelligence (AI) techniques, is pleased to announce that the annual registration for its medical device establishment with the U.S. Food and Drug Administration (FDA) has been successfully completed. Additionally, DIAGNOS would like to remind the reader that the legacy ver

BROSSARD, Quebec, Jan. 15, 2026 (GLOBE NEWSWIRE) -- Diagnos Inc. (“DIAGNOS” or the “Corporation”) (TSX Venture: ADK, OTCQB: DGNOF, FWB: 4D4A), a pioneer in early detection of critical health issues using advanced technology based on Artificial Intelligence (AI), announces the engagement of Investor Brand Network (“IBN”) to provide corporate communication and awareness solutions to the Corporation. As per the agreement signed between IBN and DIAGNOS, IBN is entitled to a monthly compensation of U